Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ESR1 degradation inducers reported to be useful for the treatment of cancer.
Dong-A ST Co. Ltd. has disclosed transcriptional enhancer factor (TEAD) and/or transcriptional coactivator YAP1/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
Head and neck squamous cell carcinoma (HNSCC), which makes up the majority of head and neck cancers, is an aggressive disease with a poor prognosis despite current multimodal treatments. Its progression is strongly linked to immune evasion and impaired immune signaling, highlighting the urgent need for new diagnostic and prognostic biomarkers to improve patient outcomes.
Researchers from Fudan University and their collaborators reported the synthesis and preclinical characterization of novel Bruton’s tyrosine kinase (BTK)-targeting proteolysis-targeting chimeras (PROTACs) based on ARQ-531, a potent, reversible, noncovalent BTK inhibitor.
Researchers at the University of Michigan designed an optimized viral protein able to boost the antitumor function of T cells. The project stemmed from observations on the particular system employed by Herpesvirus saimiri to infect T cells and hijack cellular pathways by activating them.
In their efforts to develop next-generation drugs whose structures differ from those of conventional IMiDs, researchers at Fujimoto Pharmaceutical Corp. developed FPFT-2216 through optimization of a lead compound.
In their ongoing search for effective small-molecule inhibitors of focal adhesion kinase (FAK), researchers at Beijing Normal University and collaborators started from a promising lead compound that they previously described.